| 摘要: |
| 目的：观察抗血管内皮生长因子（VEGF）雷珠单抗玻璃体内注射治疗湿性老年黄斑变性（wAMD）疗效及对患者房水炎性因子的影响。方法：前瞻性选择我院2018年1月~2020年9月112例（112眼）wAMD患者作为研究对象，采用数字表随机法分为两组，56例给予抗VEGF雷珠单抗玻璃体内注射治疗的患者设为VEGF组，56例给予光动力疗法（PDT）的患者设为PDT组，治疗前、治疗后3个月行眼科相关指标检查，并抽取房水检查炎性因子，比较两组治疗前、治疗后3个月、6个月视力变化、记录两组并发症。结果：两组治疗后3个月IOP、CNV、CMT均低于治疗前，差异有统计学意义（P＜0.05），但两组治疗前、治疗后3个月IOP、CNV、CMT差异均无统计学意义(P＞0.05)。VEGF组治疗后3个月TNF-α、IL-6水平低于治疗前，且低于PDT组，差异有统计学意义（P＜0.05）。PDT组治疗后3个月视力提高、稳定、下降的构成比例为71.43%、23.21%、5.36%；VEGF组为73.21%、25.00%、1.78%，差异均无统计学意义(P＞0.05)。治疗后6个月VEGF组视力提高率为69.64%，PDT组视力提高率为50.50%， VEGF组视力提高率明显高于PDT组，差异有统计学意义（P＜0.05）两组并发症发生率均为7.14%，差异无统计学意义(P＞0.05)。结论：抗VEGF玻璃体内注射治疗较之光动力疗法能有效控制wAMD病情，消除或减轻房水炎性反应，改善患者视力。 |
| 关键词: 抗血管内皮生长因子 湿性老年黄斑变性 疗效 房水炎性因子 影响 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Effect of intravitreal injection of anti - vascular endothelial growth factor (vegf) on wet senile macular degeneration and its effect on patients with inflammatory cytokines |
|
谢琦莲
|
|
The First Affiliated Hospital of Henan University of Science and Technology
|
| Abstract: |
| To observe the efficacy of intravitreal injection of anti-vascular endothelial growth factor (VEGF) ranibizumab in the treatment of wet age-related macular degeneration (wAMD) and its effect on the inflammatory factors in the patient's aqueous humor. Methods: We prospectively selected 112 patients (112 eyes) of wAMD in our hospital from January 2018 to September 2020 as the research subjects, and randomly divided them into two groups by using a digital table. 56 patients were given intravitreal injection of anti-VEGF ranibizumab The treated patients were set as the VEGF group, and the 56 patients who were given photodynamic therapy (PDT) were set as the PDT group. Before treatment and 3 months after treatment, the ophthalmology-related indicators were checked, and the aqueous humor was taken to check the inflammatory factors, and the two groups were compared. Before treatment, 3 months and 6 months after treatment, visual changes were recorded, and complications were recorded in the two groups. Results: The IOP, CNV and CMT of the two groups were lower than those before treatment at 3 months after treatment, and the difference was statistically significant (P＜0.05), but there was no difference in IOP, CNV, CMT between the two groups before treatment and 3 months after treatment Statistical significance (P>0.05). The levels of TNF-α and IL-6 in the VEGF group 3 months after treatment were lower than before treatment, and lower than those in the PDT group, the difference was statistically significant (P<0.05). The percentages of improved, stable, and decreased vision in the PDT group were 71.43%, 23.21%, and 5.36% after 3 months of treatment; 73.21%, 25.00%, and 1.78% in the VEGF group, and the differences were not statistically significant (P>0.05). 6 months after treatment, the visual acuity improvement rate of the VEGF group was 69.64%, and the visual acuity improvement rate of the PDT group was 50.50%. The visual acuity improvement rate of the VEGF group was significantly higher than that of the PDT group, and the difference was statistically significant (P<0.05). The incidence of complications in the two groups was 7.14%, and the difference was not statistically significant (P>0.05). Conclusion: Compared with photodynamic therapy, anti-VEGF intravitreal injection therapy can effectively control the condition of wAMD, eliminate or reduce the inflammatory response of aqueous humor, and improve the vision of patients. |
| Key words: anti-vascular endothelial growth factor Wet senile macular degeneration Curative effect Inflammatory factor of aqueous humor impact |
